No price history available.
Key financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 853,746 | 836,512 | 926,054 | 1,018,751 | 960,459 | 1,005,471 | 873,190 | N/A | N/A |
| Operating profit | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ¥m | 25,253 | -6,661 | 23,158 | -17,695 | -11,712 | 28,348 | -88,004 | N/A | N/A |
| EPS reported | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Teijin Limited, a Japanese conglomerate established in Tokyo in 1918, operates on a global scale across diverse sectors. Its core businesses encompass advanced materials, including fibers, films and sheets, and composites, as well as significant operations in healthcare and information technology. The company's materials division provides a comprehensive range of products such as high-performance aramid, carbon, and oxidized PAN fibers, along with various polyethylene materials. This segment also offers specialized items like polytrimethylene telephthalate products, artificial leather materials, polyester nanofibers, and recycled polyester fibers. Its offerings extend to polycarbonate, high-density polyethylene porous, and microporous films and sheets, in addition to PC and polyphenylene sulfide resins, molded parts, and additives. Teijin is also a specialist in composite materials, notably developing lightweight glass and carbon fiber reinforced solutions designed for the automotive industry. In the healthcare sector, Teijin develops pharmaceuticals aimed at treating bone and joint, respiratory, and cardiovascular and metabolic diseases, among others. Furthermore, it supplies an extensive array of medical devices and services, including home oxygen therapy equipment, non-invasive positive pressure ventilation systems, rehabilitation tools, and devices for sleep-disordered breathing. The company also provides a sonic accelerated fracture healing system, community-based integrated care systems, orthopedic implantable devices, and functional food ingredients. Within its IT operations, Teijin offers innovative solutions such as Recopic, a radio-frequency identification (RFID) technology tailored for efficient inventory management. Beyond its product lines, the company is actively involved in engineering solutions, tackling critical global challenges related to environmental pollution, ensuring energy supply stability, and addressing the impact of an aging workforce population.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Teijin Limited, a Japanese conglomerate established in Tokyo in 1918, operates on a global scale across diverse sectors. Its core businesses encompass advanced materials, including fibers, films and sheets, and composites, as well as significant operations in healthcare and information technology. The company's materials division provides a comprehensive range of products such as high-performance aramid, carbon, and oxidized PAN fibers, along with various polyethylene materials. This segment also offers specialized items like polytrimethylene telephthalate products, artificial leather materials, polyester nanofibers, and recycled polyester fibers. Its offerings extend to polycarbonate, high-density polyethylene porous, and microporous films and sheets, in addition to PC and polyphenylene sulfide resins, molded parts, and additives. Teijin is also a specialist in composite materials, notably developing lightweight glass and carbon fiber reinforced solutions designed for the automotive industry. In the healthcare sector, Teijin develops pharmaceuticals aimed at treating bone and joint, respiratory, and cardiovascular and metabolic diseases, among others. Furthermore, it supplies an extensive array of medical devices and services, including home oxygen therapy equipment, non-invasive positive pressure ventilation systems, rehabilitation tools, and devices for sleep-disordered breathing. The company also provides a sonic accelerated fracture healing system, community-based integrated care systems, orthopedic implantable devices, and functional food ingredients. Within its IT operations, Teijin offers innovative solutions such as Recopic, a radio-frequency identification (RFID) technology tailored for efficient inventory management. Beyond its product lines, the company is actively involved in engineering solutions, tackling critical global challenges related to environmental pollution, ensuring energy supply stability, and addressing the impact of an aging workforce population.
